KLRK1 and neoplasm: Through the development of NKAB-ErbB2 homologous recombinant antibodies, researchers have successfully enabled tumor-specific NKG2D-expressing effector cells to overcome their dependence on membrane-anchored NKG2D ligands, thereby circumventing immune evasion mechanisms [56].